NCT06489197View on ClinicalTrials.gov

AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 16, 2024

Primary Completion Date

October 30, 2026

Study Completion Date

August 30, 2027

Conditions
ESCCAdvanced Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Ivonescimab combined with albumin paclitaxel and cisplatin

Ivonescimab (20mg/kg, intravenous infusion, d1, Q3W) combined with albumin paclitaxel (220mg/m2, intravenous infusion, d1, Q3W) and cisplatin (75mg/m2, intravenous infusion, d1, Q3W), of which the maximum treatment time of chemotherapy was up to six cycles, and the maximum treatment time of AK112 was 24 months.

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER